Neostigmine
Bloxiverz, Neostigmine Methylsulfate (neostigmine) is a small molecule pharmaceutical. Neostigmine was first approved as Bloxiverz on 2013-05-31. It is used to treat drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, and urinary retention in the USA. It is known to target acetylcholinesterase.
| Trade Name | Bloxiverz, Neostigmine Methylsulfate |
|---|---|
| Common Name | Neostigmine |
| Indication | drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, urinary retention |
| Drug Class | Cholinesterase inhibitors (physostigmine type) |
